Medical Affairs at an Inflection Point

The Fierce Pharma Week Medical Affairs Advisory Board convened senior leaders across biotech and pharma to assess the structural, operational, and strategic forces reshaping the function. The conversation reflects a sector under pressure to evolve faster than its operating model allows.

Medical Affairs is entering a new phase. Expectations are expanding beyond scientific support into enterprise leadership, yet execution remains fragmented. The next era will be defined by how effectively teams translate data, technology, and stakeholder insight into coordinated action across the product lifecycle.